ObsEva SA: ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - December 1, 2022 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN) ("ObsEva" or the "Company"), a biopharmaceutical

Related Keywords

Geneva ,Genè ,Switzerland ,China ,Chinese ,Swiss ,Yuyuan Bioscience ,Shauna Dillon ,Brian Ocallaghan ,Exchange Commission ,Management Inc ,Kissei Pharmaceutical Co Ltd ,Chinese National Medical Products Administration ,Swiss Exchange ,Nasdaq ,Briano Callaghan ,Business Highlights ,Drug Evaluation ,Chinese National Medical Products ,Ebopiprant Rights ,Nasdaq Stock Market ,Third Quarter Ended September ,Organon License Agreement ,Kissei License Agreement ,Forbearance Agreement ,Nasdaq Global Select Market ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Condensed Consolidated Statements ,Obseva ,Nnounces ,Third ,Quarter ,022 ,Financial ,Results ,Rovides ,Business ,Update ,